Skip to main content

Advertisement

Table 3 Summary microRNAs used in the expression signature at each step of model development

From: MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neureceptor status in breast cancer

Rank miRNA Chromosomal location Validated mRNA targets Mean squared error Median accuracy (%) Responsea
ER status
   1 miR-342 14q32.2, intronic - 0.132 83.3 (+)
   2 miR-299-3p 14q32.31, intergenic - 0.087 100 (-)
   3 miR-217 2p16.1, intergenic - 0.07 100 (+)
   4 miR-190 15q22.2, intronic - 0.06 100 (-)
   5 miR-135b 1q32.1, intronic - 0.057 100 (-)
   6 miR-218 4p15.31, intronic LAMB3 0.047 100 (+)
PR status
   1 miR-520g 19q13.42, intergenic - 0.186 83.3 (-)
   2 miR-377 14q32.31, intergenic - 0.129 83.3 (+)
   3 miR-527-518a 19q13.42, intergenic - 0.086 100 (-)
   4 miR-520f-520c 19q13.42, intergenic - 0.07 100 (+)
HER2/neu status
   1 miR-520d 19q13.42, intergenic - 0.109 100 (+)
   2 miR-181c 19q13.12, intergenic Tcl1 0.086 100 (-)
   3 miR-302c 4q25, intronic Cyclin D1 0.062 100 (*)
   4 miR-376b 14q32.31, intergenic - 0.050 100 (+)
   5 miR-30e-3p 1p34.2, intronic Ubc9 0.047 100 (*)
  1. Summary microRNAs (miRNAs) used in the expression signature at each step of model development for oestrogen receptor (ER) status, progesterone receptor (PR) status and v-erb-b2 erythroblastic leukaemia viral oncogene homolog 2 receptors (HER2/neu) status. a(+), increased miRNA expression leads to increased probability of receptor positive status; (-), increased miRNA expression leads to increased probability of receptor negative status; (*), weak response, possibly interacting to modify the response of other miRNAs.